ARMCX2
gene geneOn this page
Also known as ALEX2KIAA0512GASP9
Summary
ARMCX2 (armadillo repeat containing X-linked 2, HGNC:16869) is a protein-coding gene on chromosome Xq22.1, encoding Armadillo repeat-containing X-linked protein 2 (Q7L311). May regulate the dynamics and distribution of mitochondria in neural cells.
This gene encodes a protein containing a potential N-terminal transmembrane domain and multiple armadillo (arm) repeats. Proteins containing arm repeats are involved in development, maintenance of tissue integrity, and tumorigenesis. This gene is located in a cluster of related genes on chromosome X. There is a pseudogene for this gene on chromosome 7. Alternative splicing in the 5’ UTR results in multiple transcript variants encoding the same protein.
Source: NCBI Gene 9823 — RefSeq curated summary.
At a glance
- GWAS associations: 1
- Clinical variants (ClinVar): 71 total — 1 pathogenic, 1 likely-pathogenic
- MANE Select transcript:
NM_177949
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:16869 |
| Approved symbol | ARMCX2 |
| Name | armadillo repeat containing X-linked 2 |
| Location | Xq22.1 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | ALEX2, KIAA0512, GASP9 |
| Ensembl gene | ENSG00000184867 |
| Ensembl biotype | protein_coding |
| OMIM | 300363 |
| Entrez | 9823 |
Gene structure
Transcript identifiers
Ensembl transcripts: 93 — 88 protein_coding, 5 protein_coding_CDS_not_defined
ENST00000328766, ENST00000330154, ENST00000356824, ENST00000413506, ENST00000431597, ENST00000433318, ENST00000440675, ENST00000458024, ENST00000467416, ENST00000475854, ENST00000479333, ENST00000488982, ENST00000496581, ENST00000889669, ENST00000889670, ENST00000889671, ENST00000889672, ENST00000889673, ENST00000889674, ENST00000889675, ENST00000889676, ENST00000889677, ENST00000889678, ENST00000889679, ENST00000889680, ENST00000889681, ENST00000889682, ENST00000889683, ENST00000889684, ENST00000889685, ENST00000889686, ENST00000889687, ENST00000889688, ENST00000889689, ENST00000889690, ENST00000889691, ENST00000937515, ENST00000937516, ENST00000937517, ENST00000937518, ENST00000937519, ENST00000937520, ENST00000937521, ENST00000937522, ENST00000937523, ENST00000937524, ENST00000937525, ENST00000937526, ENST00000937527, ENST00000937528, ENST00000937529, ENST00000937530, ENST00000937531, ENST00000937532, ENST00000937533, ENST00000937534, ENST00000937535, ENST00000937536, ENST00000937537, ENST00000937538, ENST00000937539, ENST00000937540, ENST00000937541, ENST00000937542, ENST00000937543, ENST00000937544, ENST00000937545, ENST00000937546, ENST00000937547, ENST00000971519, ENST00000971520, ENST00000971521, ENST00000971522, ENST00000971523, ENST00000971524, ENST00000971525, ENST00000971526, ENST00000971527, ENST00000971528, ENST00000971529, ENST00000971530, ENST00000971531, ENST00000971532, ENST00000971533, ENST00000971534, ENST00000971535, ENST00000971536, ENST00000971537, ENST00000971538, ENST00000971539, ENST00000971540, ENST00000971541, ENST00000971542
RefSeq mRNA: 3 — MANE Select: NM_177949
NM_001282231, NM_014782, NM_177949
CCDS: CCDS14490
Canonical transcript exons
ENST00000356824 — 6 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001295677 | 101658461 | 101658525 |
| ENSE00001307563 | 101659419 | 101659501 |
| ENSE00001318567 | 101658073 | 101658142 |
| ENSE00001322738 | 101659076 | 101659148 |
| ENSE00001347589 | 101655281 | 101657715 |
| ENSE00001423403 | 101659758 | 101659850 |
Expression profiles
Bgee: expression breadth ubiquitous, 271 present calls, max score 98.89.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 35.6105 / max 627.8758, expressed in 1412 samples.
FANTOM5 promoters (1 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 199961 | 35.6105 | 1412 |
Top tissues by expression
290 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| corpus epididymis | UBERON:0004359 | 98.89 | gold quality |
| seminal vesicle | UBERON:0000998 | 97.54 | gold quality |
| pituitary gland | UBERON:0000007 | 97.52 | gold quality |
| adrenal tissue | UBERON:0018303 | 97.29 | gold quality |
| adenohypophysis | UBERON:0002196 | 97.21 | gold quality |
| cauda epididymis | UBERON:0004360 | 96.36 | gold quality |
| right lobe of thyroid gland | UBERON:0001119 | 96.35 | gold quality |
| left lobe of thyroid gland | UBERON:0001120 | 96.07 | gold quality |
| thyroid gland | UBERON:0002046 | 95.86 | gold quality |
| caput epididymis | UBERON:0004358 | 95.65 | gold quality |
| left ovary | UBERON:0002119 | 95.21 | gold quality |
| right ovary | UBERON:0002118 | 95.20 | gold quality |
| parotid gland | UBERON:0001831 | 95.19 | gold quality |
| right adrenal gland | UBERON:0001233 | 94.84 | gold quality |
| right adrenal gland cortex | UBERON:0035827 | 94.74 | gold quality |
| stromal cell of endometrium | CL:0002255 | 94.62 | gold quality |
| adrenal cortex | UBERON:0001235 | 94.60 | gold quality |
| left adrenal gland cortex | UBERON:0035825 | 94.44 | gold quality |
| endocervix | UBERON:0000458 | 94.37 | gold quality |
| right coronary artery | UBERON:0001625 | 93.98 | gold quality |
| left adrenal gland | UBERON:0001234 | 93.75 | gold quality |
| right uterine tube | UBERON:0001302 | 93.74 | gold quality |
| body of uterus | UBERON:0009853 | 93.61 | gold quality |
| left uterine tube | UBERON:0001303 | 93.57 | gold quality |
| tibia | UBERON:0000979 | 93.55 | gold quality |
| descending thoracic aorta | UBERON:0002345 | 93.52 | gold quality |
| adrenal gland | UBERON:0002369 | 93.48 | gold quality |
| smooth muscle tissue | UBERON:0001135 | 93.45 | gold quality |
| cartilage tissue | UBERON:0002418 | 93.43 | gold quality |
| mucosa of stomach | UBERON:0001199 | 93.25 | gold quality |
Single-cell (SCXA)
Detected in 2 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | yes | 5.20 |
| E-HCAD-5 | no | 2.34 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
45 targeting ARMCX2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-9-5P | 100.00 | 72.28 | 2361 |
| HSA-MIR-223-3P | 99.99 | 70.14 | 1140 |
| HSA-MIR-1468-3P | 99.96 | 72.74 | 3797 |
| HSA-MIR-9-3P | 99.96 | 70.88 | 2068 |
| HSA-MIR-497-5P | 99.92 | 71.83 | 2674 |
| HSA-MIR-1297 | 99.91 | 73.41 | 3162 |
| HSA-MIR-7-1-3P | 99.91 | 71.53 | 4384 |
| HSA-MIR-7-2-3P | 99.91 | 71.40 | 4394 |
| HSA-MIR-15A-5P | 99.90 | 72.80 | 2787 |
| HSA-MIR-15B-5P | 99.90 | 72.78 | 2798 |
| HSA-MIR-16-5P | 99.90 | 72.80 | 2780 |
| HSA-MIR-195-5P | 99.90 | 72.81 | 2805 |
| HSA-MIR-424-5P | 99.89 | 71.90 | 2641 |
| HSA-MIR-6838-5P | 99.89 | 71.94 | 2690 |
| HSA-MIR-30A-3P | 99.87 | 69.74 | 2928 |
| HSA-MIR-30D-3P | 99.87 | 69.92 | 2917 |
| HSA-MIR-30E-3P | 99.87 | 69.68 | 2942 |
| HSA-MIR-26A-5P | 99.78 | 73.52 | 2303 |
| HSA-MIR-26B-5P | 99.78 | 73.51 | 2305 |
| HSA-MIR-320A-3P | 99.77 | 69.73 | 2107 |
| HSA-MIR-320B | 99.77 | 69.73 | 2107 |
| HSA-MIR-320C | 99.77 | 69.73 | 2107 |
| HSA-MIR-320D | 99.77 | 69.73 | 2107 |
| HSA-MIR-4429 | 99.77 | 69.62 | 2111 |
| HSA-MIR-5002-5P | 99.76 | 70.84 | 1763 |
| HSA-MIR-4719 | 99.73 | 72.10 | 3329 |
| HSA-MIR-4465 | 99.71 | 72.56 | 2096 |
| HSA-MIR-494-3P | 99.70 | 71.45 | 2795 |
| HSA-MIR-3682-3P | 99.58 | 67.63 | 865 |
| HSA-MIR-12122 | 99.56 | 69.33 | 1672 |
Literature-anchored findings (GeneRIF, showing 2)
- Data indicate that ARMCX2, COL1A1, MDK, MEST and MLH1 genes acquired methylation in drug-resistant ovarian cancer-sustaining (side population) cells. (PMID:22249249)
- ARMCX Family Gene Expression Analysis and Potential Prognostic Biomarkers for Prediction of Clinical Outcome in Patients with Gastric Carcinoma. (PMID:32685472)
Cross-species orthologs
4 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | armc10 | ENSDARG00000062960 |
| mus_musculus | Armcx2 | ENSMUSG00000033436 |
| rattus_norvegicus | Armcx2 | ENSRNOG00000025705 |
| caenorhabditis_elegans | WBGENE00013456 |
Paralogs (10): ARMCX3 (ENSG00000102401), ARMCX5 (ENSG00000125962), ARMCX1 (ENSG00000126947), ARMC12 (ENSG00000157343), GPRASP2 (ENSG00000158301), ARMC10 (ENSG00000170632), ARMCX4 (ENSG00000196440), GPRASP3 (ENSG00000198908), GPRASP1 (ENSG00000198932), ARMCX6 (ENSG00000198960)
Protein
Protein identifiers
Armadillo repeat-containing X-linked protein 2 — Q7L311 (reviewed: Q7L311)
Alternative names: ARM protein lost in epithelial cancers on chromosome X 2
All UniProt accessions (6): A0A0B4J1X4, A0A1B0GXK8, Q7L311, Q5H9D7, Q5H9E0, Q5H9E1
UniProt curated annotations — full annotation on UniProt →
Function. May regulate the dynamics and distribution of mitochondria in neural cells.
Subcellular location. Mitochondrion. Mitochondrion outer membrane.
Tissue specificity. Expressed at high levels ovary, heart, testis, prostate, brain, spleen and colon. Expressed at very low levels in liver and thymus. Not expressed in peripheral blood leukocytes. Not expressed in pancreas and ovarian carcinomas.
Similarity. Belongs to the eutherian X-chromosome-specific Armcx family.
RefSeq proteins (3): NP_001269160, NP_055597, NP_808818* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR000225 | Armadillo | Repeat |
| IPR006911 | ARM-rpt_dom | Domain |
| IPR011989 | ARM-like | Homologous_superfamily |
| IPR016024 | ARM-type_fold | Homologous_superfamily |
| IPR051303 | Armcx_regulator | Family |
Pfam: PF04826
UniProt features (15 total): region of interest 5, compositionally biased region 3, repeat 3, topological domain 2, chain 1, transmembrane region 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q7L311-F1 | 64.69 | 0.40 |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 196 (showing top):
RNGTGGGC_UNKNOWN, GOBP_AXO_DENDRITIC_TRANSPORT, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, GOZGIT_ESR1_TARGETS_DN, GOBP_ORGANELLE_TRANSPORT_ALONG_MICROTUBULE, MODULE_66, TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_SUSTAINDED_IN_ERYTHROCYTE_UP, TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_ERYTHROCYTE_UP, TGCTGAY_UNKNOWN, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_DN, GOCC_MITOCHONDRIAL_ENVELOPE, YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_13, ONDER_CDH1_TARGETS_2_UP, HTF_01, HELLER_HDAC_TARGETS_SILENCED_BY_METHYLATION_UP
GO Biological Process (0):
GO Molecular Function (1): protein binding (GO:0005515)
GO Cellular Component (3): mitochondrion (GO:0005739), mitochondrial outer membrane (GO:0005741), membrane (GO:0016020)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| binding | 1 |
| cytoplasm | 1 |
| intracellular membrane-bounded organelle | 1 |
| mitochondrial membrane | 1 |
| organelle outer membrane | 1 |
| cellular anatomical structure | 1 |
Protein interactions and networks
STRING
1193 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| ARMCX2 | SPTAN1 | Q13813 | 650 |
| ARMCX2 | RB1 | P06400 | 548 |
| ARMCX2 | WDR49 | Q8IV35 | 530 |
| ARMCX2 | HABP4 | Q5JVS0 | 511 |
| ARMCX2 | PSME3IP1 | Q9GZU8 | 508 |
| ARMCX2 | ATP6V1E2 | Q96A05 | 494 |
| ARMCX2 | CCDC69 | A6NI79 | 491 |
| ARMCX2 | DDX55 | Q8NHQ9 | 490 |
| ARMCX2 | ATPAF1 | Q5TC12 | 475 |
| ARMCX2 | BCAS4 | Q8TDM0 | 473 |
| ARMCX2 | CCDC70 | Q6NSX1 | 457 |
| ARMCX2 | ATP6V0D1 | P12953 | 446 |
| ARMCX2 | DIS3L2 | Q8IYB7 | 445 |
| ARMCX2 | ATP6V0A2 | Q9Y487 | 437 |
| ARMCX2 | ATP5F1A | P25705 | 437 |
IntAct
23 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| SLC1A1 | AGPAT2 | psi-mi:“MI:0914”(association) | 0.640 |
| TUBA4A | TXNDC9 | psi-mi:“MI:0914”(association) | 0.640 |
| HLA-DRA | ENTPD6 | psi-mi:“MI:0914”(association) | 0.530 |
| VTN | HAT1 | psi-mi:“MI:0914”(association) | 0.530 |
| ARMCX2 | LYAR | psi-mi:“MI:0915”(physical association) | 0.400 |
| VIM | ARMCX2 | psi-mi:“MI:0915”(physical association) | 0.370 |
| MAD2L2 | psi-mi:“MI:0914”(association) | 0.350 | |
| N | FLG | psi-mi:“MI:0914”(association) | 0.350 |
| ARMCX1 | GYG1 | psi-mi:“MI:0914”(association) | 0.350 |
| DNAJB2 | psi-mi:“MI:0914”(association) | 0.350 | |
| MAGEA8 | B4GALT5 | psi-mi:“MI:0914”(association) | 0.350 |
| MAGED2 | PJA2 | psi-mi:“MI:0914”(association) | 0.350 |
| MRAP2 | A2ML1 | psi-mi:“MI:0914”(association) | 0.350 |
| PPARD | LRP6 | psi-mi:“MI:0914”(association) | 0.350 |
| VSIG4 | TMEM223 | psi-mi:“MI:0914”(association) | 0.350 |
| SLC30A10 | GOLIM4 | psi-mi:“MI:0914”(association) | 0.350 |
| SLC39A12 | ESYT2 | psi-mi:“MI:0914”(association) | 0.350 |
| SLC39A2 | AGPAT2 | psi-mi:“MI:0914”(association) | 0.350 |
| SLC39A9 | TRAFD1 | psi-mi:“MI:0914”(association) | 0.350 |
| TOMM22 | DNM1L | psi-mi:“MI:2364”(proximity) | 0.270 |
| CDH5 | ESYT2 | psi-mi:“MI:2364”(proximity) | 0.270 |
| ARMCX2 | TULP3 | psi-mi:“MI:0915”(physical association) | 0.000 |
BioGRID (34): ARMCX2 (Two-hybrid), ARMCX2 (Affinity Capture-MS), ARMCX2 (Proximity Label-MS), ARMCX2 (Affinity Capture-MS), CHCHD3 (Co-fractionation), LRRC59 (Co-fractionation), ARMCX2 (Co-fractionation), ARMCX2 (Co-fractionation), ARMCX2 (Co-fractionation), ARMCX2 (Co-fractionation), ARMCX2 (Co-fractionation), ARMCX2 (Co-fractionation), KTN1 (Co-fractionation), ARMCX2 (Affinity Capture-MS), ARMCX2 (Proximity Label-MS)
ESM2 similar proteins: A3A8Q4, A3A8W6, A6QLI5, B0Y8Z0, B9F4I8, F4JFR7, F4JRP0, F4K5K6, F4KAV2, O15297, O81472, O82302, P48785, Q06003, Q0D598, Q0DZT4, Q10NB9, Q2PS26, Q4WWA0, Q5N712, Q5XUX6, Q651A1, Q6ITT4, Q6K1U0, Q6K1U4, Q6K5I0, Q6WLH4, Q6ZGY0, Q7L311, Q7TQI8, Q7XRV0, Q84T94, Q8GYY5, Q8L7S0, Q8RWN7, Q8W119, Q96JG8, Q9BE64, Q9ES73, Q9FNK5
Diamond homologs: B1WBW4, Q3UZB0, Q5H9R4, Q5JY77, Q5R4B2, Q5R7U0, Q5R9J3, Q5RDG2, Q5U310, Q5U4C1, Q5XID7, Q6A058, Q6P1M9, Q6PI77, Q7L311, Q8BHS6, Q8BUY8, Q8N2F6, Q920R4, Q96D09, Q9BE11, Q9CX83, Q9D0L7, Q9P291, Q9UH62, Q6PB60, Q71HP2, Q66HF0, Q7L4S7, Q8K3A6
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
71 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 1 |
| Likely pathogenic | 1 |
| Uncertain significance | 45 |
| Likely benign | 4 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (2)
| Variant ID | HGVS | Classification |
|---|---|---|
| 691846 | GRCh37/hg19 Xq22.1-22.2(chrX:100866604-103411980)x1 | Pathogenic |
| 442008 | GRCh37/hg19 Xq22.1(chrX:100852505-101986687)x0 | Likely pathogenic |
SpliceAI
190 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| X:101658070:AACCT:A | donor_loss | 0.9900 |
| X:101658071:ACCTG:A | donor_loss | 0.9900 |
| X:101658072:C:A | donor_loss | 0.9900 |
| X:101658490:A:AC | donor_gain | 0.9900 |
| X:101658491:C:CC | donor_gain | 0.9900 |
| X:101658493:T:TA | donor_gain | 0.9900 |
| X:101658140:GACC:G | acceptor_loss | 0.9800 |
| X:101658141:ACCT:A | acceptor_loss | 0.9800 |
| X:101658143:C:CG | acceptor_loss | 0.9800 |
| X:101658459:AC:A | donor_gain | 0.9800 |
| X:101658460:CC:C | donor_gain | 0.9800 |
| X:101658491:CTT:C | donor_gain | 0.9800 |
| X:101657716:C:CC | acceptor_gain | 0.9700 |
| X:101658068:CCAA:C | donor_gain | 0.9700 |
| X:101658138:CAGAC:C | acceptor_gain | 0.9600 |
| X:101657714:GCCT:G | acceptor_loss | 0.9200 |
| X:101657716:C:CA | acceptor_loss | 0.9200 |
| X:101658460:CCCT:C | donor_gain | 0.9200 |
| X:101658143:C:CC | acceptor_gain | 0.9100 |
| X:101658491:CTTCA:C | donor_gain | 0.9100 |
| X:101658513:T:TA | donor_gain | 0.9000 |
| X:101658140:GAC:G | acceptor_gain | 0.8700 |
| X:101658459:ACCCT:A | donor_gain | 0.8700 |
| X:101658460:CCCTC:C | donor_gain | 0.8700 |
| X:101657712:GGGC:G | acceptor_gain | 0.8500 |
| X:101658067:A:AC | donor_gain | 0.8500 |
| X:101658068:C:CC | donor_gain | 0.8500 |
| X:101658491:CT:C | donor_gain | 0.8500 |
| X:101658150:C:CT | acceptor_gain | 0.8400 |
| X:101657711:AGGGC:A | acceptor_gain | 0.8300 |
AlphaMissense
4069 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| X:101655877:A:G | L571P | 1.000 |
| X:101656111:A:G | L493P | 1.000 |
| X:101656120:A:G | L490P | 1.000 |
| X:101655706:A:G | L628P | 0.999 |
| X:101655751:A:G | L613S | 0.999 |
| X:101655877:A:T | L571H | 0.999 |
| X:101655881:C:G | A570P | 0.999 |
| X:101655889:A:G | L567P | 0.999 |
| X:101655955:A:G | L545P | 0.999 |
| X:101655994:A:G | L532P | 0.999 |
| X:101656039:A:G | L517P | 0.999 |
| X:101656124:C:G | G489R | 0.999 |
| X:101656124:C:T | G489R | 0.999 |
| X:101656221:A:C | S456R | 0.999 |
| X:101656221:A:T | S456R | 0.999 |
| X:101656223:T:G | S456R | 0.999 |
| X:101656225:A:G | L455P | 0.999 |
| X:101656246:G:T | A448D | 0.999 |
| X:101656247:C:G | A448P | 0.999 |
| X:101656254:C:A | K445N | 0.999 |
| X:101656254:C:G | K445N | 0.999 |
| X:101656291:A:T | I433N | 0.999 |
| X:101656357:A:G | L411P | 0.999 |
| X:101656366:A:C | L408W | 0.999 |
| X:101656369:G:T | A407D | 0.999 |
| X:101656405:A:G | L395P | 0.999 |
| X:101656426:A:G | L388P | 0.999 |
| X:101655736:T:C | D618G | 0.998 |
| X:101655760:A:C | I610S | 0.998 |
| X:101655760:A:T | I610N | 0.998 |
dbSNP variants (sampled 300 via entrez): RS1001017323 (X:101655207 T>A,G), RS1002710385 (X:101661512 C>G), RS1003089202 (X:101661843 T>C), RS1005848217 (X:101661817 T>C), RS1005967098 (X:101661482 A>G), RS1005999642 (X:101661038 A>C), RS1007197225 (X:101660395 A>G), RS1008837440 (X:101658898 G>A), RS1009283160 (X:101658561 A>G), RS1011872681 (X:101659930 G>C,T), RS1012878601 (X:101659812 C>G,T), RS1012995225 (X:101659417 A>G), RS1015334122 (X:101658899 G>A,T), RS1015706938 (X:101656076 G>A), RS1017797723 (X:101655235 T>C)
Disease associations
OMIM: gene MIM:300363 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
1 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST007576_17 | Chronotype | 1.000000e-11 |
EFO canonical traits (1, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0008328 | chronotype measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
37 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Air Pollutants | affects cotreatment, decreases expression, increases abundance, increases expression | 3 |
| Particulate Matter | decreases expression, increases abundance, increases expression | 3 |
| sodium arsenite | decreases methylation, increases expression | 2 |
| Valproic Acid | affects expression, increases expression, increases methylation | 2 |
| triphenyl phosphate | affects expression | 1 |
| alpha-pinene | decreases expression, increases abundance, affects cotreatment | 1 |
| pirinixic acid | affects binding, increases activity, increases expression | 1 |
| bisphenol A | increases methylation | 1 |
| terbufos | increases methylation | 1 |
| cobaltous chloride | decreases expression | 1 |
| ferrous chloride | decreases expression | 1 |
| nickel sulfate | decreases expression | 1 |
| methacrylaldehyde | increases abundance, affects cotreatment, decreases expression | 1 |
| beta-methylcholine | affects expression | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| MRK 003 | decreases expression | 1 |
| Temozolomide | decreases expression | 1 |
| Sunitinib | decreases expression | 1 |
| Acrolein | affects cotreatment, decreases expression, increases abundance | 1 |
| Vehicle Emissions | increases abundance, increases expression | 1 |
| Benzo(a)pyrene | affects methylation, increases methylation | 1 |
| Cisplatin | affects response to substance | 1 |
| Doxorubicin | increases expression | 1 |
| Fonofos | increases methylation | 1 |
| Estradiol | affects cotreatment, increases expression | 1 |
| Naled | affects expression | 1 |
| Ozone | decreases expression, increases abundance, affects cotreatment | 1 |
| Parathion | increases methylation | 1 |
| Potassium Dichromate | decreases expression | 1 |
| Silicon Dioxide | increases expression | 1 |
Cellosaurus cell lines
2 cell lines: 2 cancer cell line
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_E1QZ | HAP1 ARMCX2 (-) 2 | Cancer cell line | Male |
| CVCL_XL51 | HAP1 ARMCX2 (-) 1 | Cancer cell line | Male |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.